FDA: New Warning for Procrit, Epogen, Aranesp

Links shared publicly online about this topic.

194
total visits

FDA: New Warning for Procrit, Epogen, Aranesp

New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease puts them at risk of heart attacks, stroke, and death. More conservative dosing is needed.

View full resource at webmd.com

Tags: Anemia Medication, Urinary System, End-Stage Renal Disease, FDA, Aranesp, Procrit, Epogen, Chronic Kidney Disease

Most Recently Shared on June 24, 2011 at 10:52 pm By:

WebMD_News

FDA: New Warning for Procrit, Epogen, Aranesp: New data show that the way Procrit, Epogen, and Aranesp are used ... http://bit.ly/isAvpZ

11 months ago...

Retweet

Favorite

Also Shared By:

Heart Health

FDA: New Warning for Procrit, Epogen, Aranesp - Medications: Prescription Drugs and Over the Counter Drugs on MedicineNet.com

medicinenet.com — “Drug information on prescription and over the counter medications includes drug interactions, uses, side effects, and drug dosing.” View full resource at medicinenet.com

Most Recently Shared on June 28, 2011 at 8:24 am By:

Amanda Henson Nurse

RT @health_tweets FDA: New Warning for Procrit, Epogen, Aranesp - MedicineNet.com http://t.co/2MZ82i7

11 months ago...

Retweet

Favorite

Medical News: FDA Urges Tailored Dosing for Anemia Drugs - in Nephrology, Anemia from MedPage Today

medpagetoday.com — “To treat anemia in chronic kidney disease patients who are not on dialysis, physicians should consider starting erythropoiesis-stimulating agents (ESAs) only when hemoglobin levels drop below 10 g/dL,” View full resource at medpagetoday.com

Most Recently Shared on June 24, 2011 at 7:45 pm By:

Paul Cacciatore Patient Advocate

FDA urges lower hemoglobin targets 4 anemia drugs (Epogen, Procrit & Aranesp), but warning does not apply 2 cancer pts. http://dld.bz/ae4VA

11 months ago...

Retweet

Favorite

FDA May Limit Anemia Drug Use For Kidney Disease

huffingtonpost.com — “WASHINGTON — The Food and Drug Administration is considering new restrictions on widely used anemia drugs that appear to double the risk of stroke in patients with kidney disease. The FDA posted its safety review of the three blood-boosting medications from Amgen Inc. on Thursday, focusing on their use in patients with chronic kidney disease who are not yet sick enough to receive dialysis.” View full resource at huffingtonpost.com